The J Valve from JC Medical was linked to positive outcomes and “excellent” hemodynamic data after 30 days in an early feasibility study published in JACC: Cardiovascular Interventions. Researchers noted that the valve showed potential in patients with large aortic annuli, which represents an "unmet critical need" at this stage. 

The new expert consensus decision pathway replaces a similar document from 2019 and is to be used in conjunction with heart failure guidelines published in 2022 by the ACC, American Heart Association and Heart Failure Society of America.

The Digital Health Advisory Committee is tasked with providing perspective and recommendations on a wide variety of topics. These insights will then help the FDA draft new policies and make other important decisions.

Cardiologist Dan Blumenthal, MD, MBA, explains how changes in Medicare payments will greatly impact cardiology in the years ahead. In just a few short years, the business side of cardiology could look substantially different than it does today. 

Using a cerebral protection device during TAVR was associated with lower readmission rates, shorter hospital stays—and, yes, a lower risk of patients suffering a major stroke. A team of specialists with Cleveland Clinic shared their new findings in the Journal of the American Heart Association.

Finerenone, sold under the brand name Kerendia, is already approved by the FDA for reducing heart and kidney risks in patients with chronic kidney disease (CKD) and type 2 diabetes. Bayer plans on presenting the new data in full at ESC Congress 2024 in London. 

Bharath Krishnamurthy, a director of health policy and analytics at the American Hospital Association, explains the financial impact of current healthcare staffing shortages.

LVOT obstruction after TMVR remains a significant concern among structural heart cardiologists. Predicting the risk of LVOT obstruction typically requires CT, which comes with certain disadvantages compared to other imaging options.